AngioDynamics, Inc. (NASDAQ:ANGO) Position Reduced by Factorial Partners LLC

Factorial Partners LLC decreased its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 3.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 113,000 shares of the medical instruments supplier’s stock after selling 3,500 shares during the period. Factorial Partners LLC’s holdings in AngioDynamics were worth $1,035,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new position in AngioDynamics during the 4th quarter worth $49,000. US Bancorp DE boosted its position in shares of AngioDynamics by 1,938.0% during the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock valued at $61,000 after purchasing an additional 6,376 shares in the last quarter. Quarry LP lifted its stake in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 2,471 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in AngioDynamics in the third quarter worth approximately $86,000. Finally, SG Americas Securities LLC increased its holdings in shares of AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 2,832 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the sale, the senior vice president now directly owns 41,817 shares in the company, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Price Performance

Shares of ANGO opened at $9.29 on Friday. AngioDynamics, Inc. has a one year low of $5.26 and a one year high of $13.50. The company has a 50-day moving average of $10.78 and a two-hundred day moving average of $8.51. The stock has a market cap of $375.93 million, a price-to-earnings ratio of -1.65 and a beta of 0.60.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company’s revenue was down .1% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) EPS. Analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their target price on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, January 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.